1.Galectin-3 Reflects the Echocardiographic Grades of Left Ventricular Diastolic Dysfunction.
Uzair ANSARI ; Michael BEHNES ; Julia HOFFMANN ; Michele NATALE ; Christian FASTNER ; Ibrahim EL-BATTRAWY ; Jonas RUSNAK ; Seung Hyun KIM ; Siegfried LANG ; Ursula HOFFMANN ; Thomas BERTSCH ; Martin BORGGREFE ; Ibrahim AKIN
Annals of Laboratory Medicine 2018;38(4):306-315
BACKGROUND: The level of Galectin-3 (Gal-3) protein purportedly reflects an ongoing cardiac fibrotic process and has been associated with ventricular remodeling, which is instrumental in the development of heart failure with preserved ejection fraction (HFpEF) syndrome. The aim of this study was to investigate the potential use of Gal-3 in improved characterization of the grades of diastolic dysfunction as defined by echocardiography. METHODS: Seventy HFpEF patients undergoing routine echocardiography were prospectively enrolled in the present monocentric study. Blood samples for measurements of Gal-3 and amino-terminal pro-brain natriuretic peptide (NT-proBNP) were collected within 24 hours pre- or post-echocardiographic examination. The classification of patients into subgroups based on diastolic dysfunction grade permitted detailed statistical analyses of the derived data. RESULTS: The Gal-3 serum levels of all patients corresponded to echocardiographic indices, suggesting HFpEF (E/A, P=0.03 and E/E', P=0.02). Gal-3 was also associated with progressive diastolic dysfunction, and increased levels corresponded to the course of disease (P=0.012). Detailed analyses of ROC curves suggested that Gal-3 levels could discriminate patients with grade III diastolic dysfunction (area under the curve [AUC]=0.770, P=0.005). CONCLUSIONS: Gal-3 demonstrates remarkable effectiveness in the diagnosis of patients suffering from severe grade diastolic dysfunction. Increasing levels of Gal-3 possibly reflect the progressive course of HFpEF, as classified by the echocardiographic grades of diastolic dysfunction.
Classification
;
Diagnosis
;
Echocardiography*
;
Galectin 3*
;
Heart Failure
;
Humans
;
Prospective Studies
;
ROC Curve
;
Ventricular Remodeling
2.Whither systems medicine?
Rolf APWEILER ; Tim BEISSBARTH ; Michael R BERTHOLD ; Nils BLüTHGEN ; Yvonne BURMEISTER ; Olaf DAMMANN ; Andreas DEUTSCH ; Friedrich FEUERHAKE ; Andre FRANKE ; Jan HASENAUER ; Steve HOFFMANN ; Thomas HöFER ; Peter LM JANSEN ; Lars KADERALI ; Ursula KLINGMüLLER ; Ina KOCH ; Oliver KOHLBACHER ; Lars KUEPFER ; Frank LAMMERT ; Dieter MAIER ; Nico PFEIFER ; Nicole RADDE ; Markus REHM ; Ingo ROEDER ; Julio SAEZ-RODRIGUEZ ; Ulrich SAX ; Bernd SCHMECK ; Andreas SCHUPPERT ; Bernd SEILHEIMER ; Fabian J THEIS ; Julio VERA ; Olaf WOLKENHAUER
Experimental & Molecular Medicine 2018;50(3):e453-
New technologies to generate, store and retrieve medical and research data are inducing a rapid change in clinical and translational research and health care. Systems medicine is the interdisciplinary approach wherein physicians and clinical investigators team up with experts from biology, biostatistics, informatics, mathematics and computational modeling to develop methods to use new and stored data to the benefit of the patient. We here provide a critical assessment of the opportunities and challenges arising out of systems approaches in medicine and from this provide a definition of what systems medicine entails. Based on our analysis of current developments in medicine and healthcare and associated research needs, we emphasize the role of systems medicine as a multilevel and multidisciplinary methodological framework for informed data acquisition and interdisciplinary data analysis to extract previously inaccessible knowledge for the benefit of patients.